To the Editor:
Heparin-induced thrombocytopenia type II (HIT-II) is a life-threatening thromboembolic disorder arising from the occurrence of antibodies to heparin-platelet factor 4 complexes, and subsequent activation of platelets, thrombin generation, and damage to the vascular endothelium (1) (2) (3) . The problem is of particular importance in patients undergoing maintenance hemodialysis (HD) therapy because they are repeatedly exposed to high doses of heparin used as a routine anticoagulant during the blood purification procedures (4) . Unfortunately, HIT-II affects up to 12% of these patients dialyzed using unfractionated heparin, with low-molecular weight heparins being usually cross-reactive, and is a great challenge to attending nephrologists (1, 4) .
The American College of Chest Physicians has recently recommended some alternative anticoagulant agents for the "general population" patients with HIT-II; they include direct thrombin's inhibitors such as argatroban and lepirudin, and, to some extent, factor Xa inhibitor-danaparoid (2) . The matter is much more complicated in patients receiving HD treatment due to some clinical limitations specific for these subjects and resulting from altered drug metabolism as well as from still mysterious bleeding and, at the same time, thrombotic tendency (4) .
Argatroban (L-arginine derivative) seems to be a drug of choice in HIT-II hemodialyzed patients because of its largely hepatic clearance, no need for dose adjustment (unless there is concomitant liver dysfunction), and so far unreported anaphylactic reactions or severe bleeding complications (3, 4) . During HD procedures the drug should be administered initially as a continuous infusion of 2 µg/kg/min and aimed at activated partial thromboplastin time prolongation from 1.5 to 3.0 times compared with the predialysis value (3, 4) . Relative limitations of the prolonged argatroban use in chronic HD patients, however, could be because of its high cost and lack of an antidote (1, 3, 4) .
Lepirudin (synthetic analog of hirudin) is actually contraindicated in HD patients due to the renal clearance of the drug and a risk of its accumulation and severe bleeding complications. Despite some anecdotal reports on the successful use of lepirudin in HIT-II patients on chronic HD therapy (3, 4) , it should not be used in this clinical setting. In case of emergency, the ecarin clotting time-a simple laboratory test-should be used to monitor effects of lepirudin in such problematic HD patients. There are similar concerns with regard to another hirudin derivative, bivalirudin (3, 4) .
Danaparoid, a mixture of heparan, dermatan, and chondroitin sulfates, is not approved for HIT-II treatment in the Unites States (1, 2) . It exerts its anticoagulant action mainly by inhibiting factor Xa (anti-Xa/anti-thrombin 22:1), is renally excreted, its elimination time is 25 hours, and, unfortunately, it has no antidote. Moreover, the drug cross-reacts with up to 50% of HIT-II sera (1) . In consequence, danaparoid use in thrice weekly hemodialyzed patients may not be secure (3, 4) .
Fondaparinux (Arixtra) is a relatively new, nonimmunogenic synthetic pentasaccharide comprising of the active part of heparin molecule, binding selectively to antithrombin, and amplifying its anti-factor Xa ability more than 300 times (5, 6) . Fondaparinux is mostly excreted by the kidneys and its half-life is 17 hours when injected subcutaneously in a dose of 2.5 mg.
Although potentially unsafe in HD-dependent patients, there were recently two reports on the successful use of fondaparinux as a temporary anticoagulant (1.25 or 2.5 mg intravenously at HD onset) in two separate patients (7, 8) . The drug is not, however, amenable to neutralization by protamine sulfate and, in case of uncontrolled bleeding, may require administration of costly recombinant factor VIIa or heparinase. On the other hand, idraparinux is one of the newest pentascacharides, but its long half-life of about 70 hours seems to preclude its use as a thrice weekly anticoagulant for HD, due to the likely risk of accumulation and bleeding events (6) . So far, there were no relevant reports on idraparinux use in these patients.
SanOrg 123781A, a hexadecasaccharide, was synthesized in 1999 and represents the novel group of "heparin mimetics" (6) . Actually, its anticoagulant effects are similar to those of unfractionated heparin, but the preparation does not bind to other proteins, including crucial platelet factor 4. Till now, the drug is a subject of promising experimental studies (6) .
Sulodexide is a highly purified glycosaminoglycan preparation obtained from porcine mucosa, which is less immunogenic than bovine mucosa-derived anticoagulants (1) . It contains 80% fast-moving heparin fraction (iduronylglycosaminoglycan sulfate; 7000 D) in the bariumpropanediamine electrophoretic system and 20% dermatan sulfate. Generally, sulodexide has reduced effects on global coagulation and bleeding events compared with unfractionated heparin, may be administered either orally or intravenously, and-what deserves particular attention-is not neutralized by platelet factor 4 (9) . Recently, we used sulodexide (Vessel Due F, Alfa Wassermann, Bologna, Italy) in a maintenance HD patient of 78 years in age, with the HIT-II diagnosis based on a sudden platelet count decline of > 50% below the baseline and a highly positive heparin-induced platelet aggregation. The drug was administered at the onset of the HD procedure in a single intravenous dose of 600 LSU (lipoprotein-lipase stimulating unit; 10 LSU = 1 mg). The platelets had risen already after the first HD session to above 120 ∞ 10 9 L, and then become stable; altogether we had performed four scheduled sulodexide-anticoagulated treatments without any intradialytic thrombotic or bleeding complications. Unfortunately, she died while out of the hospital after 2 weeks, likely (no autopsy examination was performed) due to sudden cardiac arrest. Despite the poor survival not necessarily related to HIT-II complications, this could be the first report on the potential efficacy of the widely available and relatively inexpensive sulodexide in this difficult clinical setting; further studies are thus warranted. The problem, however, still remains: Which of the "anti-HIT-II" drugs in HD-dependent patients is a holy grail and which of them is a poisoned chalice?
